

Cover Story
Free
By Matthew Bin Han Ong
The Blue Ribbon Panel—a group of experts selected to identify scientific opportunities for the National Cancer Moonshot Initiative—has submitted 10 recommendations to the National Cancer Advisory Board.
By Laura Brawley
In Brief


Drugs & Targets


Trending Stories
- FDA’s second rejection of Replimune’s melanoma treatment stirs worry among oncologists, patients
“Patients are owed another review.” - Mayo Clinic AI detects pancreatic cancer up to three years before diagnosis, validation study finds
- Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
- ASCO & The Conquer Cancer Foundation announce merit awards
- CBER Director Vinay Prasad dared to “say no to drugs”
- By adding specialists to USPSTF, Kennedy would reshape the functioning and decisions of the influential health panel
Ransohoff: “The task force’s job is to describe the evidence fairly, and that’s done best with objective, detached methodologists”













